Igor Gorbatchevsky

Suggest Changes
Learn More
BACKGROUND Pixantrone dimaleate (pixantrone)--a novel aza-anthracenedione--was synthesised to reduce anthracycline-related cardiotoxicity without compromising antitumour efficacy. We aimed to assess(More)
TPS217 Background: ARQ 197 (A) is a selective, oral, non-ATP-competitive, small-molecule inhibitor of the c-MET receptor tyrosine kinase, which is implicated in tumor cell migration, invasion,(More)
527 Background: ARQ 197 selectively inhibits the c-Met receptor tyrosine kinase (RTK), which has been implicated in tumor cell migration, invasion, proliferation, and angiogenesis. CPT-11 plus C is a(More)
8523 Background: Currently, treatment options for multiply relapsed aggressive NHL are limited, and response rates are disappointing. Pixantrone, a novel aza-anthracenedione with structural(More)
  • 1